[1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66: 115-132. [2]Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67: 7-30. [3]Crosbie EJ, Kitson SJ, Mcalpine JN, et al. Endometrial cancer[J]. Lancet, 2022, 399: 1412-1428. [4]Legge F, Restaino S, Leone L, et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment[J]. Int J Gynecol Cancer, 2020, 30: 193-200. [5]Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer[J]. N Engl J Med, 2019, 380: 2317-2326. [6]Kanehira M, Harada Y, Takata R, et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis[J]. Oncogene, 2007, 26: 6448-6455. [7]Feng X, Zhang C, Zhu L, et al. DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma[J]. Oncotarget,2017, 8: 63605-63619. [8]Shen L, Li H, Liu R, et al. DEPDC1 as a crucial factor in the progression of human osteosarcoma[J]. Cancer Med, 2023, 12: 5798-5808. [9]Qu D, Cui F, Lu D, et al. DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis[J]. Cancer Sci,2019, 110: 157-165. [10]Wang Q, Jiang S, Liu J, et al. DEP Domain containing 1 promotes proliferation, invasion, and epithelial-mesenchymal transition in colorectal cancer by enhancing expression of suppressor of zest 12[J]. Cancer Biother Radiopharm, 2021, 36: 36-44. [11]贺晶,李艳,王延峰,等. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42: 1356-1361. [12]王晴晴,李爱丽,黄国锦. 含DEP结构域的蛋白质1在癌症发生发展中的作用[J]. 广西医学, 2016, 38: 1740-1743. |